Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect coronavirus (COVID-19) patients most at-risk for hospitalization or respiratory support
Joining Proactive this time out are environmental engineering company BioLargo; life sciences group VolitionRx, and digital media platform Bright Mountain Media